FDA Approval of New COVID-19 Boosters Could Come by Friday
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
The new booster targets the XBB.1.5 omicron subvariant, which is similar to the dominant variant now circulating.
The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?
Recent FDA approvals include treatments for postpartum depression, RSV in infants, pediatric constipation, metastatic colorectal cancer, and iron deficiency.
Recent FDA approvals include treatments for chronic migraine, type 1 diabetes, blood cancers, tardive dyskinesia and chorea associated with Huntington disease, vasomotor symptoms of menopause, pain and fever, and Fabry disease.
Although two states have passed laws requiring the disclosure of ingredients on menstrual product packaging, advocates want more transparency across the US.
Brella is a single-use disposable patch consisting of a sodium sheet with an adhesive overlay that is applied to a patient’s underarm by a health care provider for up to 3 minutes.
The device is implanted subcutaneously during an outpatient-compatible procedure.
Using a tetherless, adhesive fingertip sensor, the device monitors several physiological markers to detect the impairment of oxygenation due to opioid use.
Approval of the modified Opioid Analgesic REMS is expected in 2024.
March FDA approvals include treatments for candidemia and invasive candidiasis, sleep apnea for children with Down syndrome, pediatric BRAF V600E low-grade glioma, and migraines.